Prudential Financial
ARCT icon

Prudential Financial’s Arcturus Therapeutics ARCT Stock Holding History

Prudential Financial’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,710
Closed -$260K – 2694
2024
Q1 		$260K Sell
7,710
-12,500
-62% -$443K ﹤0.01% 2385
2023
Q4 		$637K Buy
+20,210
New +$480K ﹤0.01% 2031
2021
Q4 		– Sell
-8,510
Closed -$407K – 2636
2021
Q3 		$407K Buy
+8,510
New +$381K ﹤0.01% 2205

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Prudential Financial's ARCT Position: Q2 2024 in Review

Prudential Financial sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 7,710 shares — an estimated $260K sold.

Prudential Financial first reported a position in ARCT in Q3 2021 and held it in 3 quarters. The position peaked at $637K in Q4 2023. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Prudential Financial reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Prudential Financial sold 7,710 Arcturus Therapeutics shares in Q2 2024, an estimated $260K.
  • Prudential Financial first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 3 quarters.
  • Prudential Financial's Arcturus Therapeutics position peaked at $637K in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Prudential Financial's 13F filing for Q2 2024, filed 13 Aug 2024.